| Literature DB >> 32801948 |
Fatma Yasmin Mahdani1, Adiastuti Endah Parmadiati1, Diah Savitri Ernawati1, Hasrul Husain2, Sekar Alifa Putri Ekaperdana3, Ulyasari Rachmaningayu3, Priyo Hadi1, Hening Tuti Hendarti1, Meircurius Dwi Condro Surboyo1.
Abstract
BACKGROUND: Several studies have shown anti-inflammatory, anti-microbial, antifungal, and antioxidant effects from Citrus limon-peel essential oil (Cl-PEO). Cl-PEO can be developed as topical drugs for oral ulceration because of its potential active components. There have been no studies on the topical application of Cl-PEO inducing type IV hypersensitivity reaction.Entities:
Keywords: Citrus limon; essential oil; interferon gamma; interleukin 10; lymphocytes; macrophages; type IV hypersensitivity
Year: 2020 PMID: 32801948 PMCID: PMC7394596 DOI: 10.2147/JEP.S256139
Source DB: PubMed Journal: J Exp Pharmacol ISSN: 1179-1454
Figure 1The diagram of Cl-PEO test in animal.
Figure 2Type IV hypersensitivity model induced FCA in intrascapular region. (A) Point (AC) in main test. (B) applied topically Cl-PEO 0.78% (treatment group) and physiological solution (NaCl) and CMC 3% (control group) in point (D).
Components Analysis of Citrus limon Using GC-MS
| No | RT | Name of Component | % Area |
|---|---|---|---|
| 1 | 4.63 | 6-methyl-5-hepten-2-one | 0.67 |
| 2 | 6.02 | d-limonene | 75.02 |
| 3 | 6.83 | Linalool oxide | 0.39 |
| 4 | 7.18 | Trans-linalool oxide | 0.38 |
| 5 | 7.68 | Linalool | 5.63 |
| 6 | 7.93 | 1,5-dimethylbicyclo[3,2,1]octane | 0.37 |
| 7 | 8.08 | Cis-limonene oxide | 0.57 |
| 8 | 8.19 | Trans-limonene oxide | 0.94 |
| 9 | 9.22 | 2,4,6-Trimethyl-1,3,6-heptatriene | 0.79 |
| 10 | 9.50 | Decanal | 0.28 |
| 11 | 10.12 | z-citral | 3.68 |
| 12 | 10.63 | e-citral | 4.41 |
| 13 | 12.21 | Geranyl acetate | 0.33 |
| 14 | 12.60 | Isolavandulal | 0.82 |
| 15 | 12.82 | α-bergamotene | 0.38 |
| 16 | 13.76 | β-bisabolene | 0.63 |
| 17 | 15.39 | 2,7-dimethyl-2,6-octadiene | 0.24 |
| 18 | 20.76 | 2,3-dihydro-benz[d]-1,3-isothiazol-2-one | 0.12 |
| 19 | 20.87 | 6-hydroxy-2,7,7-trimethylcyclohept-2-enone | 1.11 |
| 20 | 21.01 | (z)-4-(1,5,9-trimethyl-4,8-decadienyl)-3-cyclohexen-1-one | 0.44 |
| 21 | 21.40 | Trans-2-methyl-2(4-methyl-3-pentenyl)-cyclopropanecarboxaldehyde | 0.23 |
| 22 | 36.80 | Ethyl 1-(2ʹ-2ʹ-dimethoxyethyl)-5-methoxy-2-methyl-1H-Benz(g) indole-3-carboxylate | 0.43 |
| 23 | 40.23 | t-butyldimethyl-(12-methyleicocyloxy)silane | 0.50 |
| 24 | 41.93 | 1,3-Dipalmitin trimethylsilyl ether | 1.67 |
Figure 3Number of lymphocytes using hematoxylin-eosin staining. (A) control group; (B) treatment group (observed using a light microscope with 400x magnification).
Figure 4Number of macrophages using hematoxylin-eosin staining. (A) control group; (B) treatment group (observed using a light microscope with 400x magnification).
Mean and Standard Deviation and Significant Level
| Control Group | Treatment Group | Significant Level | |
|---|---|---|---|
| 9.80±2.25 | 16.1±3.90 | 0.000 | |
| 10.5±1.84 | 16.2±1.81 | 0.000 | |
| 9.60±1.65 | 20.40±4.40 | 0.000 | |
| 3.40±0.69 | 8.50±1.36 | 0.000 |
Figure 5IFN-ɣ expression in macrophages (black arrow). (A) control group; (B) treatment group (observed using a light microscope with 400x magnification).
Figure 6IL-10 expression in macrophages (black arrow). (A) control group; (B) treatment group (observed using a light microscope with 400x magnification).